The value of microRNA-155 as a prognostic factor for survival in non-small cell lung cancer: A meta-analysis

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Wang, Fei ^a   Zhou, Jianguo ^a   Zhang, Yu ^a   Wang, Yi ^a   Cheng, Long ^a   Bai, Yuju ^a   Ma, Hu ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 155; MICRORNA; MIRN155 MICRORNA, HUMAN;

ARTICLE; ASIAN; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EUROPE; HUMAN; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; WESTERN HEMISPHERE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; GENETICS; LUNG TUMOR; META ANALYSIS; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; EUROPE; HUMANS; LUNG NEOPLASMS; MICRORNAS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84943275980     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136889     Document Type: Article

References (33)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5-29. Epub 2015/01/07. doi: 10.3322/caac.21254 PMID: 25559415.
2. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. The Lancet Oncology. 2013;14(8):777-86. Epub 2013/06/21. doi: 10.1016/s1470-2045 (13) 70254-7 PMID: 23782814.
3. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(24):3831-7. Epub 2006/08/22. doi: 10.1200/jco.2006.05.8073 PMID: 16921034.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. The New England journal of medicine. 2005;353(2):123-32. Epub 2005/07/15. doi: 10.1056/NEJMoa050753 PMID: 16014882.
5. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27(20):3277-83. Epub 2009/05/28. doi: 10.1200/jco.2008.19.4522 PMID: 19470938.
6. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013;19(8):2240-7. Epub 2013/03/09. doi: 10.1158/1078-0432.ccr-12-2246 PMID: 23470965; PubMed Central PMCID: PMCPmc3630270.
7. Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. British journal of cancer. 2010;103(8):1144-8. Epub 2010/09/23. doi: 10.1038/sj.bjc.6605901 PMID: 20859290; PubMed Central PMCID: PMCPmc2967070.
8. Wiemer EA. The role of microRNAs in cancer: no small matter. European journal of cancer (Oxford, England: 1990). 2007;43(10):1529-44. Epub 2007/05/29. doi: 10.1016/j.ejca.2007.04.002 PMID: 17531469.
9. Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Molecular cancer therapeutics. 2011;10(9):1720-7. Epub 2011/06/30. doi: 10.1158/1535-7163.mct-11-0220 PMID: 21712475.
10. Zhao J, Kelnar K, Bader AG. In-depth analysis shows synergy between erlotinib and miR-34a. PloS one. 2014;9(2):e89105. Epub 2014/02/20. doi: 10.1371/journal.pone.0089105 PMID: 24551227; PubMed Central PMCID: PMCPmc3925231.
11. Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. Journal of experimental & clinical cancer research: CR. 2010;29:151. Epub 2010/11/26. doi: 10.1186/1756-9966-29-151 PMID: 21092188; PubMed Central PMCID: PMCPmc2999592.
12. Han Z-B, Chen H-Y, Fan J-W, Wu J-Y, Tang H-M, Peng Z-H. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. Journal of Cancer Research and Clinical Oncology. 2012;138(1):153-61. WOS:000300344500017. doi: 10.1007/s00432-011-1076-z PMID: 22071603
13. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and Prognostic Value of MicroRNA-21 and MicroRNA-155 in Colorectal Cancer. Oncology. 2010;79(3-4):313-20. WOS:000289108100025. doi: 10.1159/000323283 PMID: 21412018
14. Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2013;25(1):46-54. Epub 2013/02/02. doi: 10.3978/j.issn. 1000-9604.2012.11.04 PMID: 23372341; PubMed Central PMCID: PMCPmc3555294.
15. He J, Zhang F, Wu Y, Zhang W, Zhu X, He X, et al. Prognostic role of microRNA-155 in various carcinomas: results from a meta-analysis. Disease markers. 2013;34(6):379-86. Epub 2013/03/14. doi: 10. 3233/dma-130984 PMID: 23481631; PubMed Central PMCID: PMCPmc3810250.
16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. Epub 2007/06/09. doi: 10.1186/1745-6215-8-16 PMID: 17555582; PubMed Central PMCID: PMCPmc1920534.
17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25(9):603-5. Epub 2010/07/24. doi: 10.1007/s10654-010-9491-z PMID: 20652370.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557-60. Epub 2003/09/06. doi: 10.1136/bmj.327.7414.557 PMID: 12958120; PubMed Central PMCID: PMCPmc192859.
19. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, et al. MicroRNA Classifiers for Predicting Prognosis of Squamous Cell Lung Cancer. Cancer Research. 2009;69(14):5776-83. WOS:000268360300023. doi: 10.1158/0008-5472. CAN-09-0587 PMID: 19584273
20. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al. The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non-Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts. Clinical Cancer Research. 2011;17(7):1875-82. WOS:000289054100025. doi: 10.1158/1078-0432. CCR-10-2961 PMID: 21350005
21. Gao Y, Fu S, Jiang W, Li B, Tian Y, Fu X. Association of MiR-155 expression with prognosis in resected stage III non-small cell lung cancer. Chinese Journal of Lung Cancer. 2014;17(5):417-23. doi: 10. 3779/j.issn. 1009-3419.2014.05.10 PMID: 24854560
22. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Dunant A, et al. MicroRNA expression and outcome of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program (IALT-Bio). Cancer Research. 2010;70(8).
23. Donnem T, Eklo K, Berg T, Sorbye SW, Lonvik K, Al-Saad S, et al. Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization. Journal of Translational Medicine. 2011;9.
24. Sanfiorenzo C, Ilie MI, Belaid A, Barlesi F, Mouroux J, Marquette CH, et al. Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC. PLoS ONE. 2013;8(1).
25. Sun S, Sun P, Wang C, Sun T. Downregulation of microRNA-155 accelerates cell growth and invasion by targeting c-myc in human gastric carcinoma cells. Oncology Reports. 2014;32(3):951-6. WOS:000339983200011. doi: 10.3892/or.2014.3288 PMID: 24969405
26. Yu F, Jia X, Du F, Wang J, Wang Y, Ai W, et al. miR-155-Deficient Bone Marrow Promotes Tumor Metastasis. Molecular Cancer Research. 2013;11(8):923-36. WOS:000323210500012. doi: 10.1158/1541-7786. MCR-12-0686 PMID: 23666369
27. He F, Cai L. Meta analysis of the association between the expression of microRNA-155 and the outcome of patients with lung cancer. Wei sheng yan jiu = Journal of hygiene research. 2014;43(6):1004-8. Epub 2015/01/22. PMID: 25603615.
28. Wang Y, Li J, Tong L, Zhang J, Zhai A, Xu K, et al. The prognostic value of miR-21 and miR-155 in nonsmallcell lung cancer: A meta-analysis. Japanese Journal of Clinical Oncology. 2013;43(8):813-20. doi: 10.1093/jjco/hyt084 PMID: 23817461
29. Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. European Journal of Cancer. 2013;49(3):604-15. WOS:000313947100008. doi: 10.1016/j.ejca.2012.09.031 PMID: 23099007
30. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. International journal of cancer Journal international du cancer. 2012;130(6):1378-86. Epub 2011/05/06. doi: 10.1002/ijc.26153 PMID: 21544802; PubMed Central PMCID: PMCPmc3259258.
31. Ricciuti B, Mecca C, Crino L, Baglivo S, Cenci M, Metro G. Non-coding RNAs in lung cancer. Oncoscience. 2014;1(11):674-705. Epub 2015/01/17. PMID: 25593996; PubMed Central PMCID: PMCPmc4278269.
32. Enfield KS, Pikor LA, Martinez VD, Lam WL. Mechanistic Roles of Noncoding RNAs in Lung Cancer Biology and Their Clinical Implications. Genetics research international. 2012;2012:737416. Epub 2012/08/02. doi: 10.1155/2012/737416 PMID: 22852089; PubMed Central PMCID: PMCPmc3407615.
33. Xu TP, Zhu CH, Zhang J, Xia R, Wu FL, Han L, et al. MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pacific journal of cancer prevention: APJCP. 2013;14(12):7085-90. Epub 2014/01/28. PMID: 24460255.